1.Applied Value About Posterior-Pelvic-Peritoneum Unsuture in Lymphoidectony of Gynecological Cancer
Fudan University Journal of Medical Sciences 2001;28(1):66-67
Purpose To discuss the clinical significance of posterior-pelvic-peritoneum unsuture.Methods A retrospective analysis in 218 cases accepted surgery therapy (included lymphadenectomy ),compared the state of preo-, intra-, post-operation and the incidence of postoperative complication betweenposterior-pelvic-peritoneum tnsuture group and suture group. Results The posterior-pelvic-peritoneumunsuture could shorten remain days of drainage-tube, shorten ferve period and decrease the occur rate oflymphocyst. Conclusions 1, After pelvic lymphadenectomy, posterior-pelvic-peritoneum suture can beomitted. 2, Posterior-pelvic-peritoneum unsuture can reduce the possibility of the occur rate of lymphocyst.
2.Surgical management of non-invasive uterine clear cell carcinoma.
Toru SUGIYAMA ; Satoshi TAKEUCHI ; Hiroaki ITAMOCHI
Journal of Gynecologic Oncology 2017;28(4):e55-
No abstract available.
3.9th Korea-Japan Gynecologic Cancer Joint Meeting.
Journal of Gynecologic Oncology 2012;23(1):3-4
No abstract available.
Joints
4.Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Seiji MABUCHI ; Toru SUGIYAMA ; Tadashi KIMURA
Journal of Gynecologic Oncology 2016;27(3):e31-
Clear cell carcinoma (CCC) of the ovary is known to show poorer sensitivity to chemotherapeutic agents and to be associated with a worse prognosis than the more common serous adenocarcinoma or endometrioid adenocarcinoma. To improve the survival of patients with ovarian CCC, the deeper understanding of the mechanism of CCC carcinogenesis as well as the efforts to develop novel treatment strategies in the setting of both front-line treatment and salvage treatment for recurrent disease are needed. In this presentation, we first summarize the mechanism responsible for carcinogenesis. Then, we highlight the promising therapeutic targets in ovarian CCC and provide information on the novel agents which inhibit these molecular targets. Moreover, we discuss on the cytotoxic anti-cancer agents that can be best combined with targeted agents in the treatment of ovarian CCC.
Adenocarcinoma, Clear Cell/drug therapy/*etiology/metabolism
;
Antineoplastic Agents/therapeutic use
;
Female
;
Forecasting
;
Humans
;
Neoplasm Recurrence, Local/prevention & control
;
Ovarian Neoplasms/drug therapy/*etiology/metabolism
5.Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).
Shunsuke OHNISHI ; Hidemichi WATARI ; Maki KANNO ; Yoko OHBA ; Satoshi TAKEUCHI ; Tempei MIYAJI ; Shunsuke OYAMADA ; Eiji NOMURA ; Hidenori KATO ; Toru SUGIYAMA ; Masahiro ASAKA ; Noriaki SAKURAGI ; Takuhiro YAMAGUCHI ; Yasuhito UEZONO ; Satoru IWASE
Journal of Gynecologic Oncology 2017;28(5):e44-
OBJECTIVE: Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by cisplatin. We investigated whether rikkunshito could improve chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients treated with cisplatin. METHODS: Patients with uterine cervical or corpus cancer who were to receive cisplatin (50 mg/m² day 1) and paclitaxel (135 mg/m² day 0) as first-line chemotherapy were randomly assigned to the rikkunshito group receiving oral administration on days 0–13 with standard antiemetics, or the control group receiving antiemetics only. The primary endpoint was the rate of complete control (CC: no emesis, no rescue medication, and no significant nausea) in the overall phase (0–120 hours). Two-tailed p<0.20 was considered significant in the planned analysis. RESULTS: The CC rate in the overall phase was significantly higher in the rikkunshito group than in the control group (57.9% vs. 35.3%, p=0.175), as were the secondary endpoints: the CC rate in the delayed phase (24–120 hours), and the complete response (CR) rates (no emesis and no rescue medication) in the overall and delayed phases (63.2% vs. 35.3%, p=0.095; 84.2% vs. 52.9%, p=0.042; 84.2% vs. 52.9%, p=0.042, respectively), and time to treatment failure (p=0.059). Appetite assessed by visual analogue scale (VAS) appeared to be superior in the rikkunshito group from day 2 through day 6. CONCLUSION: Rikkunshito provided additive effect for the prevention of CINV and anorexia.
Administration, Oral
;
Anorexia*
;
Antiemetics
;
Appetite
;
Cisplatin*
;
Drug Therapy
;
Dyspepsia
;
Eating
;
Herbal Medicine*
;
Humans
;
Japan
;
Nausea*
;
Paclitaxel*
;
Time-to-Treatment
;
Vomiting*
6.Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB–IIB cervical cancer
Koji MATSUO ; Muneaki SHIMADA ; Tsuyoshi SAITO ; Kazuhiro TAKEHARA ; Hideki TOKUNAGA ; Yoh WATANABE ; Yukiharu TODO ; Ken ichirou MORISHIGE ; Mikio MIKAMI ; Toru SUGIYAMA
Journal of Gynecologic Oncology 2018;29(1):e11-
OBJECTIVE: To examine the surgical-pathological predictors of para-aortic lymph node (PAN) metastasis at radical hysterectomy, and for PAN recurrence among women who did not undergo PAN dissection at radical hysterectomy. METHODS: This is a retrospective analysis of a nation-wide cohort study of surgically-treated stage IB–IIB cervical cancer (n=5,620). Multivariate models were used to identify independent surgical-pathological predictors for PAN metastasis/recurrence. RESULTS: There were 120 (2.1%) cases of PAN metastasis at surgery with parametrial involvement (adjusted odds ratio [aOR]=1.65), deep stromal invasion (aOR=2.61), ovarian metastasis (aOR=3.10), and pelvic nodal metastasis (single-node aOR=5.39 and multiple-node aOR=33.5, respectively) being independent risk factors (all, p<0.05). Without any risk factors, the incidence of PAN metastasis was 0.9%, while women exhibiting certain risk factor patterns (>20% of the study population) had PAN metastasis incidences of ≥4%. Among 4,663 clinically PAN-negative cases at surgery, PAN recurrence was seen in 195 (4.2%) cases that was significantly higher than histologically PAN-negative cases (2.5%, p=0.046). In clinically PAN-negative cases, parametrial involvement (adjusted hazard ratio [aHR]=1.67), lympho-vascular space invasion (aHR=1.95), ovarian metastasis (aHR=2.60), and pelvic lymph node metastasis (single-node aHR=2.49 and multiple-node aHR=8.11, respectively) were independently associated with increased risk of PAN recurrence (all, p<0.05). Without any risk factors, 5-year PAN recurrence risk was 0.8%; however, women demonstrating certain risk factor patterns (>15% of the clinically PAN-negative population) had 5-year PAN recurrence risks being ≥8%. CONCLUSION: Surgical-pathological risk factors proposed in this study will be useful to identify women with increased risk of PAN metastasis/recurrence.
Cohort Studies
;
Female
;
Humans
;
Hysterectomy
;
Incidence
;
Lymph Nodes
;
Neoplasm Metastasis
;
Odds Ratio
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Uterine Cervical Neoplasms
7.Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma:the JGOG 3018 Trial
Takashi MOTOHASHI ; Akira YABUNO ; Hiroshi MICHIMAE ; Tetsuro OHISHI ; Miwa NONAKA ; Masashi TAKANO ; Shin NISHIO ; Hiroyuki FUJIWARA ; Keiichi KEIICHI ; Eiji KONDO ; Toru SUGIYAMA ; Tsutomu TABATA
Journal of Gynecologic Oncology 2021;32(1):e9-
Objective:
The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m2 every 4 weeks. While 40 mg/m2 has recently been used in clinical practice, evidence supporting this use remains lacking.
Methods:
This phase III randomized, non-inferiority study compared progressionfree survival (PFS) for patients with platinum-resistant ovarian carcinoma between an experimental arm (40 mg/m2 PLD) and a standard arm (50 mg/m2 PLD) until 10 courses, disease progression or unacceptable toxicity. Eligible patients had received ≤2 prior lines.Stratification was by performance status and PFS of prior chemotherapy (<3 months versus ≥3 months). The primary endpoint was PFS and secondary endpoints were overall survival (OS), toxicity profile, clinical response and tolerability. The total number of patients was 470.
Results:
The trial was prematurely closed due to slow recruitment, with 272 patients randomized to the experimental arm (n=137) and standard arm (n=135). Final analysis was performed with 234 deaths and 269 events for PFS. In the experimental arm vs. standard arm, median PFS was 4.0 months vs. 4.0 months (hazard ratio [HR]=1.065; 95% confidence interval [CI]=0.830–1.366) and median OS was 14.0 months vs. 14.0 months (HR=1.078; 95% CI=0.831–1.397). Hematologic toxicity and oral cavity mucositis (≥grade 2) were more frequent in the standard arm than in the experimental arm, but no difference was seen in ≥grade 2 hand-foot skin reaction.
Conclusion
Non-inferiority of 2 PLD dosing schedule was not confirmed because the trial was closed prematurely. However, recommendation of dose reduction of PLD should be based both on efficacy and safety.
8.The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG
Eiji KONDO ; Tsutomu TABATA ; Nao SUZUKI ; Daisuke AOKI ; Hideaki YAHATA ; Yoshio KOTERA ; Osamu TOKUYAMA ; Keiichi FUJIWARA ; Eizo KIMURA ; Fumitoshi TERAUCHI ; Toshiyuki SUMI ; Aikou OKAMOTO ; Nobuo YAEGASHI ; Takayuki ENOMOTO ; Toru SUGIYAMA
Journal of Gynecologic Oncology 2020;31(6):e94-
Objective:
In this study we sought to investigate the clinical factors that affect postprogression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC).We utilized the JGOG3017/Gynecological Cancer InterGroup data to compare paclitaxel plus carboplatin (TC) and irinotecan plus cisplatin (CPT-P) in the treatment of stages I to IV CCC.
Methods:
We enrolled 166 patients with recurrent or persistent CCC and assessed the impact of variables, including platinum sensitivity, treatment arm, crossover chemotherapy, primary stage, residual tumor at primary surgery, performance status, ethnicity, and tumor reduction surgery at recurrence on the median of PPS in patients with recurrent or persistent CCC.
Results:
A total of 77 patients received TC, and 89 patients received CPT-P. The median PPS for patients with platinum-resistant disease was 10.9 months, compared with 18.8 months for patients with platinum-sensitive disease (hazard ratio [HR]=1.88; 95% confidence interval [CI]=1.30–2.72; log-rank p<0.001). In the multivariate analysis, the platinum sensitivity (resistant vs. sensitivity; HR=1.60; p=0.027) and primary stage (p=0.009) were identified as independent predictors of prognosis factors for PPS in recurrent or persistent CCC.
Conclusions
Our findings revealed that platinum sensitivity and primary stage are clinical factors that significantly affect PPS in patients with recurrent or persistent CCC as wellas other histologic subtypes of ovarian cancer. PPS in patients with recurrent CCC should establish the basis for future clinical trials in this population.
9.Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
Aikou OKAMOTO ; Eiji KONDO ; Toshiaki NAKAMURA ; Satoshi YANAGIDA ; Junzo HAMANISHI ; Kenichi HARANO ; Kosei HASEGAWA ; Takeshi HIRASAWA ; Kensuke HORI ; Shinichi KOMIYAMA ; Motoki MATSUURA ; Hidekatsu NAKAI ; Hiroko NAKAMURA ; Jun SAKATA ; Tsutomu TABATA ; Kazuhiro TAKEHARA ; Munetaka TAKEKUMA ; Yoshihito YOKOYAMA ; Yoichi KASE ; Shuuji SUMINO ; Junpei SOEDA ; Ajit SURI ; Daisuke AOKI ; Toru SUGIYAMA
Journal of Gynecologic Oncology 2021;32(2):e16-
Objective:
To evaluate the efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer.
Methods:
This Phase 2 open-label, single-arm study enrolled Japanese women with homologous recombination deficiency-positive relapsed, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who had completed 3–4 lines of therapy. The starting dose of niraparib was 300 mg administered once daily in continuous 28-day cycles until objective progressive disease, unacceptable toxicity, consent withdrawal or discontinuation. The primary endpoint, objective response rate (ORR), was assessed by the investigator using RECIST version 1.1. Safety evaluations included the incidence of treatment-emergent adverse events (TEAEs), including serious TEAEs.
Results:
Twenty women were enrolled and the confirmed ORR in the full analysis set (FAS) was 35.0% (7/20), consisting of 1 complete response and 6 partial responses. Disease control rate in the FAS was 90.0%. The most frequently reported TEAEs (>50%) were anemia, nausea, and platelet count decreased. One patient (5.0%) had TEAEs leading to discontinuation of niraparib whereas reductions or interruptions were reported in 14 (70.0%) and 15 (75.0%) patients, respectively. The median dose intensity (202.9 mg daily) corresponded to a relative dose intensity of 67.6%.
Conclusion
Efficacy and safety of niraparib in heavily pretreated Japanese women was comparable to that seen in an equivalent population of non-Japanese women. No new safety signals were identified.
10.Awareness Survey on Genetic Testing among Pharmacists in Hiroshima City
Kayo IKEDA ; Toru HOSOI ; Michiko YOSHII ; Masanori SUGIYAMA ; Koichiro OZAWA
Japanese Journal of Social Pharmacy 2022;41(1):56-68
In this study, we aimed to clarify awareness regarding genetic testing among pharmacists in Hiroshima City to contribute to regional medical care provided in pharmacies. Pharmacists should consider the advantages and disadvantages of being able to easily receive genetic tests. We conducted an awareness survey on genetic testing among pharmacists belonging to the Hiroshima Pharmaceutical Association, at 645 pharmacies in Hiroshima City. Responses were received from 674 pharmacists, yielding a response rate of 43.4% (280 pharmacies). In response to the question, “Can you perform genetic testing at a pharmacy?”, 6.7% of pharmacists answered yes and 65.4% said this was impossible. Among the 92.4% of pharmacists other than those available, 79.6% answered “I am worried about my knowledge of genetic testing,” followed by 39.3% “cannot take the time,” 29.2% “hurdles for new business,” 28.1% “problems such as pharmacy facilities to protect personal information,” and 15.7% “ethical difficulties.” From the age difference, pharmacists do not carry out genetic testing even if they have knowledge; they need to make an ethical judgment to determine whether to conduct genetic testing. Additionally, although pharmacies provide medication guidance and protect personal information, 28.1% of pharmacists answered that there are problems with their pharmacy’s ability to protect personal information when handling “genetic information.” Pharmacists should consider it critical to treat “genetic information” as personal information, with the utmost care and understanding.